Fleckenstein A, Fleckenstein-Grün G, Byon Y K, Haastert H P, Späh F
Arzneimittelforschung. 1979;29(2):230-46.
Niludipine (bis(2-propoxyethyl)1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate; Bay a 7168) with respect to its specific actions on mammalian myocardium, sino-auricular or atrio-ventricular pacemakers, myometrium, and vascular smooth muscle has to be considered one of the most potent representatives of the new group of calcium antagonists. The pharmacodynamic effects of niludipine strikingly resemble those of nifedipine both qualitatively and quantitatively. Interestingly enough, niludipine is also a powerful coronary vasodilator. This is made particularly evident by the present experiments on potassium- or glycoside-contractured smooth musculature originating from large extramural coronary stem arteries.
尼鲁地平(双(2 - 丙氧基乙基)1,4 - 二氢 - 2,6 - 二甲基 - 4 - (3 - 硝基苯基) - 3,5 - 吡啶二羧酸酯;Bay a 7168)就其对哺乳动物心肌、窦房结或房室起搏器、子宫肌层和血管平滑肌的特定作用而言,必须被视为新型钙拮抗剂组中最有效的代表之一。尼鲁地平的药效学作用在定性和定量方面都与硝苯地平极为相似。有趣的是,尼鲁地平也是一种强大的冠状动脉血管扩张剂。这在目前对源自大型壁外冠状动脉主干的钾或糖苷收缩的平滑肌组织进行的实验中尤为明显。